12 January 2018
The Raindrop corneal inlay from ReVision Optics and the AcuFocus Kamra corneal inlay have been implanted in thousands of eyes. Ninety-five percent of patients with these devices report being quite satisfied, according to surveys, and virtually all implanting surgeons report they would recommend the procedures to their colleagues.
28 December 2017
NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the conclusion of the Russian Ministry of Industry and Trade on the compliance of the production site of NovaMedica Innotech R&D center, a subsidiary of NovaMedica, with the Russian Good Manufacturing Practice (GMP) standards.
29 August 2017
Maxim Gorbachev, Managing Partner of RMI Partners: "New technologies make dramatic changes to business. They even reached financing of venture capital companies. Use of crypto-currency has resulted into development of the new mechanism of crowdfunding – Initial Coin Offering (ICO) which is in a way similar to public share placement (IPO). Venture projects utilize blockchain technologies to create and sell digital tokens, thus raising funds from investors. When initially ICO was used as mechanism to develop new crypto-currency instruments such as Ethereum, nowadays ICO serve as a democratic mechanism of fund raising for any project. And this instrument cannot be ignored due to amounts of funds raised this way."
11 August 2017
Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.
29 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.
30 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
17 January 2018
Synthetic biologists have long dreamed of designing genetic circuits in the body that can produce drugs in response to environmental cues. But it’s been a challenging task. Now scientists at Rice University say they’ve created a toolkit of gene “promoters” that can turn genes on and off at command.
17 January 2018
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.
16 January 2018
After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the journal Science provides an in-depth and timely review of the key developments that have led to several successful gene therapy treatments for patients with serious medical conditions.
16 January 2018
A draft federal law on the introduction of medicinal products for human use into civil circulation was prepared by the Russian Ministry of Health. The bill proposes to establish a more effective legal regulation of relations associated with the elaboration, application and enforcement of requirements in the area of circulation of medicinal products for human use, namely, by establishing a mechanism for release control of medicines coming into the civil circulation in Russia.